A single infusion using Nobel Prize-winning CRISPR gene-editing technology has freed patients with hereditary angioedema from the painful, unpredictable swelling attacks that had defined their lives — with many coming off long-term medication entirely after just one treatment.
At a glance
- Hereditary angioedema: A rare genetic condition affecting roughly one in 50,000 people, causing erratic bouts of swelling in the lips, throat, bowels, hands, and feet — sometimes severe enough to cause suffocation and death.
- CRISPR gene therapy: Ten patients in the UK, New Zealand, and the Netherlands received a single infusion of nanolipids designed to enter liver cells and switch off the gene responsible for overproducing a protein that triggers dangerous swelling.
- Phase-one trial results: Multiple patients have remained attack-free for 18 months or more, with results published in the New England Journal of Medicine and larger trials now under way.
What the therapy does
Hereditary angioedema is caused by a mutation in the C1 inhibitor gene. When this gene stops working, the body overproduces a protein called kallikrein, which drives a buildup of bradykinin — the protein responsible for leaky blood vessels and swelling. Attacks can strike as often as twice a week and last anywhere from hours to days.
The new therapy uses CRISPR, the gene-editing system that earned its developers the Nobel Prize in Chemistry in 2020 C.E., to deliver nanolipid particles into liver cells. Once there, they knock out the kallikrein gene, stopping the chain reaction at its source. The result is not symptom management — it appears to be a genuine halt to the disease process itself.
Dr. Hilary Longhurst, principal investigator at the University of Auckland, said the single-dose approach appeared to provide a permanent cure for what she described as “very disabling symptoms” in her patients. Dr. Padmalal Gurugama, a consultant in clinical immunology and allergy at Cambridge University Hospital, put it plainly: “My patient was having attacks every three weeks and that gentleman has not had any attacks in the past 18 months. He is not taking any medications. That is amazing.”
What patients say
For people who have lived with hereditary angioedema, the change has been profound. Cleveland, a 54-year-old from Suffolk who took part in the trial, has been free from attacks since receiving the therapy 18 months ago. “The randomness, unpredictability and potential severity of the attacks has made trying to live my life almost impossible,” he said. “I spent my life constantly wondering if my next attack would be severe.”
Judy Knox, a nurse in New Zealand, described the therapy as “like a medical magic wand.” Before her diagnosis, she endured abdominal swelling, vomiting, and severe pain lasting days at a time. Dental work once triggered dangerous swelling in her mouth that threatened her airway. Knox previously managed her condition with androgen medication — a supply that was not always reliable — and is now off it entirely. “It’s changed my life,” she said.
The science behind the promise
The phase-one trial involved just 10 patients, but its results have drawn wide attention from researchers. Prof. Paul Morgan, an immunologist at Cardiff University, called the findings remarkable. “They demonstrate the potential to permanently cure HAE with a single treatment,” he said. Dr. Michael Tarzi, a senior lecturer and honorary consultant at Brighton and Sussex Medical School, described it as “an outstanding application of new technology.”
The research builds on a wave of advances in CRISPR-based medicine that have accelerated in recent years. A separate CRISPR therapy for sickle cell disease received regulatory approval in the U.S. and U.K. in late 2023 C.E., signaling that gene editing is moving from laboratory promise to clinical reality. Doctors have already treated 25 more patients in a phase-two trial and are recruiting for a phase-three trial, which will test the therapy across different hereditary angioedema types and populations.
A real but important caveat
The therapy is not expected to reach patients soon. Even if it clears the remaining trials, one-shot gene therapies rank among the most expensive treatments in the world, with recent estimates placing them between $1 million and $2 million per patient. Prof. Morgan noted that this could limit access to wealthy countries, raising serious questions about equity that larger trials will not resolve on their own. The path from a promising phase-one result to a widely available treatment is long, and for a rare disease affecting one in 50,000 people, commercial incentives may complicate that journey further.
Still, for patients who have spent decades managing a condition that can be disfiguring, isolating, and life-threatening, the results published in the New England Journal of Medicine represent something that rigorous, peer-reviewed science rarely delivers so cleanly: genuine hope of a cure.
Read more
For more on this story, see: The Guardian
For more from Good News for Humankind, see:
- U.K. cancer death rates down to their lowest level on record
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
